{"id":1516,"date":"2016-11-07T12:16:28","date_gmt":"2016-11-07T12:16:28","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1516"},"modified":"2025-05-05T10:27:05","modified_gmt":"2025-05-05T04:57:05","slug":"mercks-antibody-for-clostridium-difficile","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile","title":{"rendered":"Merck\u2019s Antibody for Clostridium Difficile"},"content":{"rendered":"<p style=\"text-align: left;\">Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration\u2019s Antimicrobial Drugs Advisory Committee voted 10 to 5 with 1 abstention to recommend its approval. In October 2016, bezlotoxumab commercialized as Zinplava, got approved by the panel. Zinplava is a selective, human immunoglobulin G monoclonal antibody designed to neutralize&nbsp;<em>C. difficile<\/em>&nbsp;toxin B.<\/p>\n<p style=\"text-align: left;\">Toxin B can damage the gut wall and cause inflammation, leading to the symptoms of&nbsp;C. difficile&nbsp;enteritis, which include abdominal pain and watery diarrhea. This infection is basically caused by bacteria and occurs mostly in patients residing in hospitals and nursing homes who might have taken certain antibiotics or some other medications. The incidence of&nbsp;this&nbsp;infection is higher in certain patient populations, including people 65 years of age or older, and in patients with compromised immune systems due to an underlying disease or from treatment.<\/p>\n<p style=\"text-align: left;\">Zinplava was developed by researchers at UMass Medical School\u2019s Mass Biologics along with Medarex (now part of Bristol-Myers Squibb), and licensed to Merck in 2009 for development as a potential therapeutic for&nbsp;<em>C. difficile<\/em>&nbsp;infection. After the threat given to the company by eroding Cubicin&#8217;s patent protection&nbsp;in court&#8211;and the Supreme Court&#8217;s decision in May 2016 not to take up the case- this decision has been a much needed achievement for the company. Merck will make Zinplava available in first quarter of 2017.<\/p>\n<p>&nbsp;<\/p>\n<p><em>Insight by:<br \/>\n<\/em><em>Sukhvinder Singh<br \/>\n<\/em><em>Associate Analyst<br \/>\n<\/em><em>DelveInsight Business Research<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration\u2019s Antimicrobial Drugs Advisory Committee voted 10 to 5 with 1 abstention to recommend its approval. In October 2016, bezlotoxumab commercialized as Zinplava, got approved by the panel. Zinplava is a selective, human immunoglobulin [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[638,637,204,395],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-1516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-antibody","tag-c-difficile","tag-delveinsight","tag-merck","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Merck\u2019s Antibody for Clostridium Difficile - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration\u2019s\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Antibody for Clostridium Difficile - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration\u2019s\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-07T12:16:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T04:57:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12065833\/Antibody_iStock_0000388818441966617140.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"333\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck\u2019s Antibody for Clostridium Difficile - DelveInsight Business Research","description":"Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration\u2019s","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Antibody for Clostridium Difficile - DelveInsight Business Research","og_description":"Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration\u2019s","og_url":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-11-07T12:16:28+00:00","article_modified_time":"2025-05-05T04:57:05+00:00","og_image":[{"width":500,"height":333,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12065833\/Antibody_iStock_0000388818441966617140.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile","url":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile","name":"Merck\u2019s Antibody for Clostridium Difficile - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12065833\/Antibody_iStock_0000388818441966617140.jpg","datePublished":"2016-11-07T12:16:28+00:00","dateModified":"2025-05-05T04:57:05+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration\u2019s","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/mercks-antibody-for-clostridium-difficile#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12065833\/Antibody_iStock_0000388818441966617140.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12065833\/Antibody_iStock_0000388818441966617140.jpg","width":500,"height":333},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12065833\/Antibody_iStock_0000388818441966617140-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">C.difficile<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Merck<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody<\/span>","<span class=\"advgb-post-tax-term\">C.difficile<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 7, 2016","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Nov 7, 2016 12:16 pm","modified":"Updated on May 5, 2025 10:27 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1516"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1516\/revisions"}],"predecessor-version":[{"id":31621,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1516\/revisions\/31621"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1517"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1516"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1516"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}